Cebranopadol: novel dual opioid/NOP receptor agonist analgesic
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12461
Abstract: Chronic pain presents a difficult clinical challenge because of the limited efficacy, the limiting adverse‐effect profile or the abuse potential of current analgesic options. Cebranopadol is a novel new agent in clinical trials that combines… read more here.
Keywords: opioid nop; dual opioid; novel dual; cebranopadol novel ... See more keywords
Cebranopadol, a novel first-in-class drug candidate: Method validation and first exploratory pharmacokinetic study in rabbits.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of veterinary pharmacology and therapeutics"
DOI: 10.1111/jvp.12948
Abstract: Cebranopadol is a novel, centrally acting, potent, first-in-class analgesic drug candidate with a unique mode of action that combines nociceptin/orphanin FQ peptide receptor and opioid peptide receptor agonism. The present study aimed to develop and… read more here.
Keywords: drug candidate; method; cebranopadol novel; method validation ... See more keywords